B
대웅제약
069620KOSPI의약품 제조업57.3 / 100
Reference Date: 2026-04-13
Financial Score24.5 / 40
News Sentiment13.8 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE significantly exceeds the industry average but the high debt ratio poses financial risk. Declined 10.1% over the past month, and news sentiment is positive.
Company InformationBased on 2025 Annual Report
Business Overview
Daewon Pharmaceutical, established in 2002, is a leading pharmaceutical company specializing in the production and sales of specialty drugs and high-purity botulinum toxin 'Nabohta'. In 2025, it achieved sales of 13.91 trillion KRW and operating profit of 2.04 trillion KRW, driven by global market expansion, AI-based digital healthcare solutions, and R&D investments in innovative drugs.
Number of Employees
1,794people
Average Salary
77.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
9.03Industry Average 14.806.5Point
Lower than industry avg (good)
PBR
1.54Industry Average 1.042.5Point
Higher than industry avg (caution)
ROE
18.71Industry Average 4.427.0Point
4.2x industry avg (excellent)
Debt Ratio
56.35Industry Average 11.980.0Point
4.7x industry avg (risky)
Trend 2023~20258.5 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲6.9% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲26.8% (2-year basis)
ROE Trend
3.5 / 4
Avg ROE 11.9% (improving, 3yr)
Detailed News Sentiment
45 totalPositive 8Neutral 32Negative 0Average Sentiment Score 55.8
- Neutral
- Neutral
- Neutral
Detailed Momentum
52-week position3.0Point
52w lower range (32%)
Current 150,400Won52-week high 194,00052-week low 129,200
1-month return1.0Point
1m -10.05% (falling)
Volume trend5.0Point
Volume flat
Detailed Disclosure
8 totalPositive 0Neutral 8Negative 0
- Neutral투자판단관련주요경영사항2026-04-10
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
- Neutral주식등의대량보유상황보고서(일반)2026-03-27
- Neutral정기주주총회결과2026-03-26
- Neutral최대주주등소유주식변동신고서2026-03-26